tirzepatide and psoriatic arthritis Concomitant ixekizumab significantly improved disease activity and promoted weight reduction versus ixekizumab alone in adults with PsA and obesity or overweight in the TOGETHER-PsA phase 3b trial. Read Mounjaro and Psoriatic Arthritis: Interactions

The veterinary market offers potential for technology transfer to human applications

Llorente-Berzal A, Puighermanal E, Burokas A, Ozaita A, Maldonado R, Marco EM, et al

While this test identifies your genetic predispositions to GLP-1 response, it doesn't predict medication shelf lifebut it does help personalize your treatment protocol for optimal results

Tirzepatide is a firstinclass glucosedependent insulinotropic polypeptide and glucagonlike peptide1 receptor agonist once weekly injectable approved for the treatment of type 2 diabetes mellitus and is currently in phase III development for chronic weight management

Weight loss was greater in female participants (up to 30.8%) than male participants (23.2%) at 80 weeks, a sex difference consistent with Phase 2 findings according to Dr